{"url_path":"/sec/espr/8-k/2026-06-01/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-039518-index.html","accession_number":"0001628280-26-039518","cik":"0001434868","ticker":"ESPR","issuer_name":"Esperion Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1434868/0001628280-26-039518-index.html","primary_entity_key":"0001434868","primary_entity_name":"Esperion Therapeutics, Inc."},"word_count":350,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\nThe Company held its Annual Meeting on May 28, 2026. As of the close of business on March 31, 2026, the record date for the Annual Meeting, there were 257,404,876 shares of Common Stock outstanding and entitled to vote at the Annual Meeting. The number of shares of Common Stock present in person or represented by proxy at the Annual Meeting was 177,208,856, thus establishing a quorum for the transaction of business at the Annual Meeting. The Company’s stockholders voted on the following matters, which are described in detail in the Proxy Statement: (i) to elect two Class I director nominees, J. Martin Carroll and Sheldon L. Koenig, to the Company's Board of Directors, each to hold office until the Company's 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”), (ii) to approve the non-binding advisory resolution on the compensation of the Company’s named executive officers (“Proposal 2”), (iii) to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 3”), and (iv) to approve an amendment to the 2022 Plan to increase the aggregate number of shares of Common Stock authorized for issuance under the 2022 Plan by 7,000,000 shares (\"Proposal 4\").\n\nThe Company’s stockholders approved the Class I director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for Class I directors as follows:\n\nClass I Director NomineeForWithholdBroker Non-Votes\n\nJ. Martin Carroll\n105,082,56526,011,48946,114,802\n\nSheldon L. Koenig109,672,94121,421,11346,114,802\n\nThe Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:\n\nForAgainstAbstainBroker Non-Votes\n\n95,650,22634,866,033577,79546,114,802\n\nThe Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows:\n\nForAgainstAbstainBroker Non-Votes\n\n167,083,4478,765,2731,360,136—\n\nThe Company’s stockholders approved Proposal 4. The votes cast at the Annual Meeting were as follows:\n\nForAgainstAbstainBroker Non-Votes\n\n108,150,21322,489,001454,84046,114,802\n\nNo other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting."}